Methods of inhibiting choroidal neovascularization
AssigneeUniversity of Pennsylvania
InventorsRong Wen, Zhijun Luo, Alan M. Laties
Life of this patent
Estimating the term…
Abstract
The present invention relates to compositions and methods for inhibiting unwanted angiogenesis, particularly those of ocular tissues. The treatment, inhibition, and/or prevention of choroidal neovasculature (CNV) is provided, along with an animal model for CNV and imaging techniques that permit the screening of potential agents as anti-angiogenesis and anti-CNV agents.
Claims21
A method of administration of an ophthalmic formulation, comprising administering the ophthalmic formulation to a human by placement of the formulation into the vitreous or by placement of the formulation between the conjunctiva and the sclera of an eye of the human, wherein the formulation comprises rapamycin and a second component comprising polyethylene glycol.
A method of administration of an ophthalmic formulation, comprising intravitreal or subconjunctival injection of the ophthalmic formulation into an eye of a human, wherein the formulation comprises polyethylene glycol and an agent selected from the group consisting of rapamycin, tacrolimus, everolimus, pimecrolimus, and temsirolimus.
A method of administration of an ophthalmic formulation, comprising intravitreal injection of the ophthalmic formulation into an eye of a human, wherein the formulation comprises rapamycin and a second component comprising polyethylene glycol.
Dependencies are inferred from the claim text.